Agilent Acquires Biocare Medical for $950M
Agilent announced it has entered into a definitive agreement to acquire Biocare Medical from an investor group led by Excellere Partners and GHO Capital Partners, in an all-cash transaction valued at $950M. Biocare has achieved annual double-digit revenue and profit growth since 2021 and generated over $90M in revenue in 2025. The deal is expected to be accretive to Agilent's top-line growth rate, margin profile and non-instrument revenue mix in the first year. The transaction is expected to become accretive to Agilent's EPS approximately 12 months following close. The transaction is subject to customary closing conditions, including receipt of regulatory approvals, and is expected to close by no later than Agilent's fourth fiscal quarter of 2026. Upon close, Biocare will become part of the Agilent Life Sciences and Diagnostics Markets Group.
